J Cancer 2021; 12(24):7445-7453. doi:10.7150/jca.64661 This issue

Research Paper

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer

Xuben Hou1, Jintong Du2✉, Hao Fang1✉

1. Department of Medicinal Chemistry and Key Laboratory of Chemical Biology of Natural Products (MOE), Cheeloo College of Medicine, School of Pharmaeutical Science, Shandong University, Jinan, Shandong, 250012, China.
2. Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, 250117, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Hou X, Du J, Fang H. PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer. J Cancer 2021; 12(24):7445-7453. doi:10.7150/jca.64661. Available from https://www.jcancer.org/v12p7445.htm

File import instruction


Graphic abstract

As a member of protein tyrosine phosphatases (PTPs), the protein tyrosine phosphatase receptor type O (PTPRO) has attracted increasing attention for its important roles in cell signaling. Currently, the roles of PTPRO in human cancers remain elusive. Herein, we performed bioinformatic analyses and revealed the potential oncogenic role of PTPRO in specific cancer types. Further in vitro experiments indicated that inhibition of PTPRO suppresses the proliferative abilities of tumor cells in pancreatic cancer, blood cancer, and breast cancer. Moreover, small molecular PTPRO inhibitor could induce cell apoptosis and affect the cell cycle in pancreatic cancer. In addition, PTPRO expression promoted the infiltration of CD8+ T, macrophages, dendritic cells, and neutrophils, in pancreatic cancers. Our findings suggested PTPRO may serve as a potential drug target for pancreatic cancer.

Keywords: PTPRO, prognosis, biomarker, pancreatic cancer, tumor-infiltrating